NeoImmuneTech
Mary Beth Muench-Holum is an experienced professional in the field of clinical operations, with a background in gene therapy, immuno-oncology, and pharmaceutical development. Mary Beth has held various leadership roles in companies such as NeoImmuneTech, Novartis Gene Therapies, Abbott, and Astellas Pharma. Mary Beth has a Bachelor of Science in Chemistry from Loras College, as well as Master's degrees in Pharmacology from Loyola University Chicago and Loyola University Stritch School of Medicine Graduate Program.
This person is not in any offices
NeoImmuneTech
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. Our lead drug candidate, NT-I7, is the only clinical-stage long acting rhIL-7, and is uniquely positioned to address unmet medical needs in Immuno-Oncology and Infectious Diseases such as COVID-19. IL-7 is a fundamental cytokine for lymphocyte development, survival, and memory development. Furthermore, NT-I7 has been shown clinically to have desired PK/PD and safety profiles, making it an ideal combination partner with T-cell targeted therapies as well as vaccines. NT-I7 is being studied in multiple clinical trials and many in collaboration with industry leaders in I-O, including Merck, BMS, and Roche for CPI combination trials. Follow us on Twitter @neoimmunetech